Compare Boston Scientific Corporation (BSX) vs Nutrien Ltd (NTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Nutrien Ltd — how do they compare? Boston Scientific Corporation trades at $50.71 (market cap $74.19B), while Nutrien Ltd trades at $66.76 (market cap $32.05B). The key difference: Boston Scientific Corporation is far larger — about 2.3× Nutrien Ltd's market cap, and Nutrien Ltd pays a 3.27% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | NTR | |
|---|---|---|
Market Cap | $74.19B | $32.05B |
Sector | Health | Basic Materials |
52-Week High | $108.14 | $83.94 |
52-Week Low | $42.63 | $53.64 |
Enterprise Value | $86.27B | $43.86B |
Dividend Yield | — | 3.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BSX trades at $50.46, up 2.33% today, with strong earnings beats in recent quarters and a bullish technical trend. Revenue grew to $20.07B in 2025, with net income margin expanding to 17.5%. The stock shows robust institutional support and insider buying, while facing near-term headwinds from competitive pressures in key segments like WATCHMAN.
Outlook remains positive with 86% analyst buy ratings and a $67.21 consensus price target, implying 33% upside. Risks include guidance cuts and market share losses, but solid cash flow and valuation metrics support long-term growth potential for patient investors.
Nutrien (NTR) trades at $66.31, up 2.93% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported Q2 2026 earnings of $2.61 per share, missing estimates, though revenues benefited from higher potash prices. Fundamentals show solid profitability with 8.44% net margin and reasonable valuation at P/E of 13.62. Recent dividend declarations of $0.55 per share demonstrate shareholder returns commitment.
NTR presents value opportunity with analyst consensus target of $76.17 (15% upside) and strong buy ratings (61%). However, earnings volatility, declining cash flow trends, and agricultural cycle sensitivity pose risks. The stock's appeal hinges on execution amid input cost pressures and global fertilizer demand recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Nutrien Ltd
Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with roughly 20% share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
Read more on NTR →
